New Therapeutic Approach for Brain Tumors: Intranasal Administration of Ras Inhibitor Perillyl Alcohol976

摘要

INTRODUCTION: Historically, recurrent glioblastoma (GBM) has a median survival of 3 to 6 months. Since active Ras contribute to malignant phenotype of these bra.